Drug pricing has entered the U.S. presidential campaigns with two Democratic candidates vowing to make government control over pricing part of their platform. Hillary Clinton is the latest to join the fray, saying she would unveil a plan to regulate drug prices in the U.S. Earlier this month, a primary opponent, Sen. Bernie Sanders (I-Vt.), introduced legislation that would authorize Medicare to directly negotiate prices with drugmakers and allow patients, pharmacists and wholesalers to import prescription drugs from licensed pharmacies in Canada, where drugs are cheaper.

The U.S. Patent and Trademark Office launched Patentsview, a new patent data visualization platform that allows the public to explore technological, regional and individual-level patent trends dating back to 1976. In linking inventors, their organizations, locations and overall patenting activity, the database will eliminate the redundant cleaning, converting and matching of data by many individual researchers.

The FDA issued additional and revised draft guidance on product-specific bioequivalence studies to support generic drug applications. The guidance provides new recommendations for 40 drugs and revises the guidance for 18 other drugs, according to a notice published in the Federal Register. Comments on the guidance are due by Nov. 20.